Veinplicity for Improved Venous Access: The VIVA Trial

Physeon

Status and phase

Terminated

Phase 3

Conditions

Difficult-to-access Veins for Intravenous Cannulation

Treatments

Device: Tourniquet

Device: Veinplicity with tourniquet

Study type

Interventional

Funder types

Industry

Other

Identifiers

NCT03752632

PHY0011

Details and patient eligibility

About

This study will assess the safety and effectiveness of the Veinplicity device to improve the visualization and palpability of difficult-to-access veins for intravenous cannulation.

Full description

This is a prospective, randomized controlled study that will assess ability of Veinplicity to improve successful peripheral vein cannulation at the first stick in enrolled subjects. Potential subjects will undergo a peripheral vein assessment by a study clinician, which is standard of care prior to peripheral vein cannulation (PVC) for the establishment of intravenous (IV) access. Adults who are assessed as having "fair or poor" vein quality will be consented, enrolled and randomized into the study. Subjects will be randomized in a 1:1 ratio to either (1) tourniquet alone (control group); or (2) Veinplicity with tourniquet (treatment group). The primary endpoint is first-stick success. Clinicians will use an 18-, 20- or 22-gauge cannula. Clinician and subject satisfaction will be separately assessed using surveys on Day 0. Subjects in both groups will be followed for one day (either phone or in-hospital visit) after enrollment for safety. Qualified study clinicians must have at least one year of experience inserting peripheral IVs and must perform an average of five PVCs per week. The primary hypothesis to be tested is: Veinplicity with tourniquet is superior to tourniquet alone for successful peripheral vein access at first stick when used to cannulate subjects assessed as having a fair or poor level of vein quality. It is expected that this study will enroll approximately 246 subjects; 123 per study group. It is expected that up to five sites will be involved in this study. A planned interim analysis will be conducted to reassess the study planned sample size when approximately 50% of subjects have been enrolled. Enrollment will not stop during the interim analysis activities. Safety will be evaluated by the collection and analysis of the incidence and severity of all procedure- and/or device-related adverse events through the Day 1 phone call/visit.

Enrollment

120 patients

Sex

All

Ages

22+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject is ≥ 22 years old.
Subject is assessed as having fair or poor vein quality.
Subject's both arms are suitable for cannulation.
Subject will not suffer harm from a delay in having an IV established as determined by the treating clinician.

Exclusion criteria

Subject has existing intravenous access.
Subject has a planned or existing intra-arterial access.
Subject has broken, infected or irritated skin and/or dermatological conditions, e.g., eczema, psoriasis and/or allergic reactions, on either forearm.
Subject has an active implantable medical device.
Subject wears a transdermal drug delivery patch on her/his forearm.
Subject has an active/suspected deep vein thrombosis or thrombophlebitis, impaired circulation, impaired sensation, active/uncontrolled bleeding, recently radiated tissue, recent fracture, recent injury or surgery resulting in blood loss > 100 mL, osteoporosis, localized abscess, localized tuberculosis, and/or a chronic wound with potential underlying osteomyelitis.
Subject has impaired cognition or communication (unable to provide accurate feedback).
Subject has a history of seizures and/or epilepsy, and/or a recent seizure, possible recent seizure or a history of possible seizures.
Subject is pregnant and/or breastfeeding at the time of study enrollment.
Subject has, at the site of or in between Veinplicity electrode application sites, an active/suspected malignancy.